Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2015
Price : $35 *
At a glance
- Drugs Liver cancer stem cell therapy (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 18 Dec 2013 Status changed from active, no longer recruiting to completed, as reported by a media release from California Stem Cell.
- 13 Dec 2013 A full data readout is expected early in 2014, according to a media release from Cellular Biomedicine Group.
- 13 Dec 2013 The final patient has been treated, according to a media release from Cellular Biomedicine Group.